DARATUMUMAB MONOTHERAPY FOR PATIENTS WITH INTERMEDIATE-RISK OR HIGH-RISK SMOLDERING MULTIPLE MYELOMA: A RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE 2 STUDY (CENTAURUS)
This phase II trial was designed to evaluate the benefit of daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma. The 24-month progression-free survival rate ranged from 75.3% to 89.9%, depending on dosing intensity. Phase III trials to evaluate daratumumab monotherapy in smoldering multiple myeloma are warranted. https://www.nature.com/articles/s41375-020-0718-z#citeas
